The present study was aimed to investigate the prognostic scope of MGMT by evaluating both its promoter methylation status and protein expression in a series of primary malignant glioma patients with varied histologies treated with alkylating agent, Temozolomide and radiotherpay. The gene discussed is MGMT; the disease is malignant glioma.